TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29141361
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg twice daily for day 0 to day 3 after PCI
Study: 18306904
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional therapy only)
Study: 21372624
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Treatment (CBT)
Study: 23607895
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Treatment supported by Information and Communication Technologies (CBT + ICT)
Study: 21310077
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (lisinopril, losartan, atorvastatin)
Study: 15378097
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (referrals to physical therapy and/or rehabilitation)
Study: 11331630
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix, 0.25 mg daily during late follicular phase)
Study: 21945081
Drug: Low-dose bupivacaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bupivacaine
Study: 30866853
Drug: PCV13 vaccine
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 vaccine serotypes
Study: 28395984
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy (MT) including neurodynamic techniques, functional massage, and carpal bone mobilization
Study: 28395984
Drug: Electrophysical Modalities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysical Modalities (EM) including laser and ultrasound therapy
Study: 17148774
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and cyclophosphamide administered concurrently
Study: 17148774
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and cyclophosphamide administered sequentially
Study: 12962749
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with polyclonal or monoclonal antilymphocytic antibodies associated with cyclosporine and prednisone (n=201)
Study: 10078748
Drug: withdrawn from
Approvals — FDA: no, EMA: no, PMDA: no
Description: withdrawn from therapy (n = 4)
Study: 8742561
Drug: Intensive diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetes treatment
Study: 8742561
Drug: Conventional diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diabetes treatment
Study: 3316309
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg + Amiloride 5 mg
Study: 1682228
Drug: Diuretic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic group
Study: 25744453
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs) with organoleptic masking (L-menthol, aspartame, thaumatin, cinnamon) and physical masking
Study: 25744453
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs) with physical masking
Study: 25744453
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablets (ODTs) without organoleptic masking
Study: 10841922
Drug: Glyceroltrinitrate (GTN;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyceroltrinitrate (GTN; 0.4 mg/h)
Study: 10841922
Drug: Glyceroltrinitrate (GTN;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyceroltrinitrate (GTN; 0.4 mg/h) + Vitamin C (Vit-C; 55 μg/kg/min)
Study: 10841922
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (Vit-C; 55 μg/kg/min) alone
Study: 8905031
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of L-asparaginase (L-ASE) 10,000 IU/sqm every three days during the induction phase (8 doses, first exposure)
Study: 8905031
Drug: Conventional or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional or high doses of L-asparaginase (L-ASE) during the second or third exposures (high-dose L-ASE 25,000 IU/sqm weekly for a total of 20 doses)
Study: 22805300
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml isotonic saline (placebo)
Study: 12051112
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (Menorest, 50 micrograms)
Study: 9797622
Drug: Both morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both morphine and diamorphine
Study: 7618661
Drug: 51W89 besylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51W89 besylate 0.1 mg.kg‐1
Study: 7618661
Drug: 51W89 besylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51W89 besylate 0.15 mg.kg‐1
Study: 7618661
Drug: 51W89 besylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51W89 besylate 0.2 mg.kg‐1
Study: 7916551
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg.kg‐1
Study: 368703
Drug: Chlorprothixene 50
Normalized name: chlorprothixene 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene 50 mg b.d. (twice daily) to outpatients
Study: 368703
Drug: Chlorprothixene 50
Normalized name: chlorprothixene 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene 50 mg every 6 hours to inpatients for 5 days
Study: 28891826
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 0.375% ropivacaine
Study: 21806387
Drug: CYP2C19 genotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotypes (gene-dose effect)
Study: 17098626
Drug: Epaxal (aluminium-free,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaxal (aluminium-free, virosome-adjuvanted vaccine)
Study: 17098626
Drug: Havrix (aluminium-adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix (aluminium-adsorbed HAV vaccine)
Study: 15517641
Drug: Corticosteroid (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (80 mg triamcinolone acetonide)
Study: 9332238
Drug: alpha 1-antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha 1-antitrypsin augmentation therapy
Study: 29331635
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg sotatercept
Study: 29331635
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg sotatercept
Study: 29331635
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg sotatercept
Study: 29331635
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg sotatercept
Study: 29331635
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg sotatercept
Study: 29331635
Drug: Sotatercept (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (all doses)
Study: 27636206
Drug: HMW carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMW carbohydrate solution (1.2 g•kg•bw‐1 of 10%)
Study: 27636206
Drug: LMW carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMW carbohydrate solution (1.2 g•kg•bw‐1 of 10%)
Study: 27636206
Drug: HMW vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMW vs LMW carbohydrate solutions
Study: 27636206
Drug: Both HMW
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HMW and LMW carbohydrate solutions
Study: 22335889
Drug: Short-term psychotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychotherapy (solution-focused or psychodynamic therapy, combined)
Study: 25454120
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy
Study: 16314604
Drug: Paroxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (up to 50 mg/day for 31 days)
Study: 6871773
Drug: Zomepirac 100
Normalized name: zomepirac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomepirac 100 mg administered 30 minutes preoperatively
Study: 6871773
Drug: Zomepirac 100
Normalized name: zomepirac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomepirac 100 mg administered one hour preoperatively
Study: 6871773
Drug: Zomepirac 200
Normalized name: zomepirac
DrugBank: Zomepirac (DB04828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomepirac 200 mg administered one hour preoperatively
Study: 27513901
Drug: PGA monotherapy
Normalized name: PGA
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGA monotherapy
Study: 27513901
Drug: PGA combination
Normalized name: PGA
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGA combination regimens
Study: 27513901
Drug: Non-PGA medications
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PGA medications
Study: 27513901
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (not on any topical medications)
Study: 24962242
Drug: PGB-CR 330
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB-CR 330 mg
Study: 24962242
Drug: PGB-CR 165
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB-CR 165 mg
Study: 16043801
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d ethyl‐EPA
Study: 10457698
Drug: Office-based vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vision therapy with supplementary home therapy
Study: 10457698
Drug: Home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapy only
Study: 34185
Drug: Propranolol (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (daily doses increasing up to 3 g)
Study: 34185
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean therapeutic level of 1600 mg/day)
Study: 34185
Drug: Propranolol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (dose increase related to hypertensive encephalopathy)
Study: 26819451
Drug: R-CHOP treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP treatment in ABC patients
Study: 24332997
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 325mg daily for 6 weeks
Study: 23067321
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily for 12 weeks
Study: 11530128
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg continuously during four 28-day cycles) + Medroxyprogesterone acetate (10 mg), Norethindrone acetate (1 mg), or Placebo (last 14 days of each cycle)
Study: 11530128
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg continuously during four 28-day cycles) + Medroxyprogesterone acetate (10 mg), Norethindrone acetate (1 mg)
Study: 15481766
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + C (ephedrine 20 mg and caffeine 200 mg) in hypertensive patients treated with antihypertensive agents other than beta-blockers
Study: 15481766
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in hypertensive patients under any antihypertensive treatment
Study: 8302451
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium naproxen (550 mg) immediately after induction of anesthesia (Group I)
Study: 8302451
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium naproxen (550 mg) at the end of surgery (Group II)
Study: 8302451
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline immediately after induction of anesthesia (Group III)
Study: 3327697
Drug: Intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nifedipine infusion
Study: 3327697
Drug: Intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nifedipine infusion with additional propranolol
Study: 27492789
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylphenidate (MPH)
Study: 29229652
Drug: Individualised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised treatment by general practitioners based on pathophysiological phenotyping and individualised treatment goals.
Study: 29229652
Drug: Individualised lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised lifestyle intervention (web-based and face-to-face) to improve daily physical activity and dietary changes.
Study: 16966110
Drug: Acupuncture (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (three outpatient treatments with eight needles applied to bilateral points LI4, SP6, UB31, and UB32)
Study: 8774286
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg three times per day for > or = 3 days)
Study: 26281857
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Group Therapy (ACT-G)
Study: 24911421
Drug: Problem-solving intervention
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving intervention (PSI) consisting of 2 home visits and 18 telephone calls over a 3-month intensive intervention and a 9-month maintenance period. Both groups received monthly information letters in addition to usual care.
Study: 24911421
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving usual care and monthly information letters.
Study: 19851115
Drug: elvitegravir/r (150/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: elvitegravir/r (150/100 mg once daily) plus maraviroc (150 mg twice daily)
Study: 19851115
Drug: maraviroc (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: maraviroc (150 mg twice daily) before or after elvitegravir/r (150/100 mg once daily)
Study: 19851115
Drug: elvitegravir/r (150/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: elvitegravir/r (150/100 mg once daily)
Study: 18021205
Drug: TCA 33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCA 33% solution
Study: 16027889
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy (cell suspension from immature nervous and hemopoietic tissues injected into the subarachnoidal space)
Study: 12370107
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg finasteride/day
Study: 12370107
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride/day
Study: 15248876
Drug: IMZ implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMZ implants
Study: 1315825
Drug: Candoxatril 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 10 mg
Study: 1315825
Drug: Candoxatril 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 50 mg
Study: 28799232
Drug: Professionally administered
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally administered plaque removal (PAPR) and photodynamic therapy (PDT)
Study: 19803579
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy (3 individual sessions)
Study: 8243858
Drug: Simvastatin (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10‐20 mg/day)
Study: 3896661
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 10% clotrimazole cream
Study: 3896661
Drug: Twice-daily application
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily application of 2% clotrimazole cream for 3 days
Study: 25031188
Drug: Low-dose thiazide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thiazide diuretics (12.5 mg/day of hydrochlorothiazide)
Study: 25031188
Drug: No thiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thiazide diuretics
Study: 18570306
Drug: DUAL 1500
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DUAL 1500 (1500 mg R1626 bid + peginterferon alfa‐2a)
Study: 18570306
Drug: DUAL 3000
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DUAL 3000 (3000 mg R1626 bid + peginterferon alfa‐2a)
Study: 18570306
Drug: TRIPLE 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIPLE 1500 (1500 mg R1626 bid + peginterferon alfa‐2a + ribavirin)
Study: 16029797
Drug: 2.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 Gy fraction (total dose 15.0 Gy)
Study: 16029797
Drug: 5.0 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 Gy fraction (total dose 30.0 Gy)
Study: 11925390
Drug: Thyrotrophin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin-releasing hormone (TRH) infusion
Study: 11925390
Drug: Dopaminergic type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic type 2 (DA2) receptor blockade
Study: 2205571
Drug: Xylocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine (1 mg/kg iv)
Study: 7430412
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate capsules
Study: 7430412
Drug: Enteric-coated erythromycin
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated erythromycin base tablets
Study: 28232972
Drug: V-shaped toothbrush
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V-shaped toothbrush (Oral-B Ortho)
Study: 26005776
Drug: Atorvastatin (20mg/day)
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (20mg/day)
Study: 23942231
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (specific study)
Study: 21336838
Drug: CHO mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO mouth rinse (25 ml)
Study: 17192510
Drug: Innovator 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator 0.005% latanoprost ophthalmic solution
Study: 17192510
Drug: Cyclodextrin-containing latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclodextrin-containing latanoprost ophthalmic solution
Study: 15149259
Drug: Intergroup competition
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intergroup competition (combination of competition and cooperation)
Study: 2730278
Drug: m-chlorophenylpiperazine (mCPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (mCPP) administered intravenously
Study: 31559634
Drug: Topiramate 50-100
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50-100 mg/day to week 36
Study: 25344375
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 mcg/d, N=80)
Study: 25226738
Drug: Natural honey
Normalized name: Robitussin Cough Drop Herbal With Natural Honey Center
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural honey (70 g daily for 4 weeks)
Study: 18817597
Drug: Supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised treatment (10 mg amodiaquine/kg and 4 mg artesunate/kg daily for 3 days, directly observed in hospital)
Study: 18817597
Drug: Unsupervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised treatment (first dose supervised, remaining doses taken at home)
Study: 10747828
Drug: trovafloxacin 200
Normalized name: trovafloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trovafloxacin 200 mg od
Study: 9484878
Drug: ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 500 mg bd
Study: 10747828
Drug: lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lomefloxacin 400 mg od
Study: 1893812
Drug: verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 80 mg orally every 6 hr for 10 doses
Study: 1893812
Drug: diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 60 mg by mouth as one dose
Study: 7065521
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum concentration of theophylline (20 mg/L)
Study: 7065521
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum concentration of theophylline (10 mg/L)
Study: 28353600
Drug: Gum-chewing (sugarless
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum-chewing (sugarless gum, 3 times daily for at least 15 minutes until postoperative exhaust defecation)